

RECORDATI: UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

Milan, 28 October 2014 – Further to the press release dated 20 October 2014 and always within the Recordati's share buy-back program announced on 9 October 2014 with the object of purchasing Recordati ordinary shares for the servicing of current and future stock option plans in favor of certain group employees, the Company informs the following purchase transactions, pursuant to art. 87 bis of Consob Regulation 11971/1999 ("Issuers Regulations").

SUMMARY OF TRANSACTIONS FROM 20 TO 27 OCTOBER 2014					
Date	Type of Transaction	Financial Instrument	Quantity	Average price	Consideration Euro
20.10.2014	Purchase	Ord. Shares Recordati	80,000	12.1186	969,491.20
21.10.2014	Purchase	Ord. Shares Recordati	83,000	12.0710	1,001,888.85
22.10.2014	Purchase	Ord. Shares Recordati	2,252	12.1903	27,452.58
TOTAL			165,252		1,998,832.63

Please note that between 20th to 27th October 2014 the Company has sold n. 40,000 in Treasury stock in favor of beneficiaries of Company's stock options plans in force, further to the exercise of options granted to them by these stock options plans. The sell price is equal to the exercise price fixed upon the granting of such options.

In the light of the above, on 27 October 2014, the Company has n. 5,080,170 own shares in Treasury stock which amount to 2.429% of the current share capital.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa and in the United States of America. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases. Consolidated revenue for 2013 was € 941.6 million, operating income was € 195.4 million and net income was € 133.7 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke

(39)0248787393

e-mail: inver@recordati.it

Media Relations

Studio Noris Morano

(39)0276004736, (39)0276004745

e-mail: norismorano@studionorismorano.com

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale
VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.
REG. IMP. MILANO N. 00748210150
CODICE FISCALE/P.IVA 007482210150
R.E.A. MILANO N. 401832

and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.